الفهرس 
Chapter I: chronic myeloid leukemiaOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
In our study we investigated 50 subjects of CML (23 males and 27 females) and 32 control (16 males and 16 females) age ranged between 18 and 75 years.
The studied patients were divided into two groups according to their response to imatinib: group I (responder to Imatinib) included 27 CML patients (12 males and15 females), their age ranged between 18-75 years, and group II (non-responder to Imatinib ) included 23 patients, (11 males and12 females) their age ranged between 18-75years .
All subjects were submitted to the followings: History taking, clinical examination, and laboratory investigations. These include detection of CYP2B6 G15631T gene polymorphism using conventional PCR. The results of this study revealed that:
There was no significant difference in age and gender between both patients and controls.
There was no significant difference in clinical data among patients.
There was no significant difference in comorbid disease among patients.
There was no significant difference in BM aspiration and Philadelphia among patients.
There was significant difference in BCR-ABL at different periods among patients.
There was no significant difference in type of treatment among patients.
There was no significant difference survival rate among patients.
There was no significant difference between patients and controls regarding CYP2B6 G15631T genotype polymorphism.
There was no significant difference between patients and controls regarding CYP2B6 G15631T genotype polymorphism in male patients.
There was no significant difference between patients and controls regarding CYP2B6 G15631T genotype polymorphism in female patients.
There was no significant difference between responders & non responders regarding CYP2B6 G15631T genotype polymorphism.
There was no significant difference between responders & non responders regarding CYP2B6 G15631T genotype polymorphism in male patients.
There was no significant difference between responders & non responders regarding CYP2B6 G15631T genotype polymorphism in female patients.